DOI: 10.1128/aac.00905-26 ISSN: 0066-4804

Activity of oral β-lactams, tebipenem and ceftibuten, combined with novel oral β-lactamase inhibitors against broad-spectrum β-lactamase-producing Escherichia coli

Christophe Le Terrier, Emilien Aubonney, Patrice Nordmann, Laurent Poirel
Show PDF Cite

ABSTRACT

Oral ceftibuten and tebipenem, alone or combined with avibactam, ledaborbactam, or xeruborbactam, were evaluated against recombinant Escherichia coli producing 57 acquired β-lactamases. Tebipenem showed greater intrinsic activity than ceftibuten against extended-spectrum β-lactamase (ESBL) and AmpC producers. Whereas avibactam and ledaborbactam remained inactive against metallo-β-lactamases, xeruborbactam restored activity against most class B producers. Tebipenem-xeruborbactam demonstrated the broadest inhibitory spectrum and the lowest MIC values overall. This combination may represent a promising oral option for complicated urinary tract infections.

More from our Archive